Atif M, Bashir A, Ahmad N, Fatima RK, Saba S, Scahill S (2017). Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients. BMC Infectious Diseases 17(1):655.
Crossref

Breen R, Smith CBH (2004). Paradoxical Reactions during Tuberculosis Treatment in Patients with and without HIV Co-Infection. Thorax 59:704-707.
Crossref

Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N (2010). High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. The International Journal of Tuberculosis and Lung Disease 14(4):413-419.

Chattu VVK, Kumaryy S (2015). TB-HIV co-infection and MDR-TB : major concerns for post 2015 global agenda Editorial TB-HIV Co-Infection and MDR-TB : Major Concerns for Post 2015 Global Agenda. International Journal of Current Microbiology and Applied Sciences 4:1-5.

Carnevali S, Petruzzelli S, Longoni B, Vanacore R, Barale R, Cipollini M, Scatena F, Paggiaro P, Celi A, Giuntini C (2003). Cigarette smoke extract induces oxidative stress and apoptosis in human lung fibroblasts. American Journal of Physiology-Lung Cellular and Molecular Physiology 284:955-963.
Crossref

Deiss R, Rodwell T, Garfein R (2009). Tuberculosis and Drug Use: Review and Update. Clinical Infectious Diseases 48:72-82.
Crossref

Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AMV, Satyanarayana S, Parmar M, Moonan PK, Lo TQ (2015). Patient and Provider Reported Reasons for Lost to Follow Up in MDR-TB Treatment: A Qualitative Study from a Drug Resistant TB Centre in India. PLoS ONE 10(8):135802.
Crossref

Desissa F, Workineh T, Beyene T (2018). Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa. Public Health, pp. 1-6.
Crossref

Duarte R, Santos A, Mota M, Carvalho A, Marques A, Barros H (2011). Involving Community Partners in the Management of Tuberculosis among Drug Users. Public Health 125: 60-62.
Crossref

Dye C, Williams BG (2000). Criteria for the control of drug-resistant tuberculosis. Proceedings of the National Academy of Sciences, 97(14): 8180-8185.
Crossref

Eklund D (2013). Mycobacterium tuberculosis and the human macrophage - shifting the balance through inflammasome activation (Issue 1372).
Crossref

Escombe AR, Moore DA, Gilman RH, Pan W, Navincopa M, Ticona E, Martínez C, Caviedes L, Sheen P, Gonzalez A, Noakes CJ (2008). The infectiousness of tuberculosis patients coinfected with HIV. PLoS Medicine 5:9.
Crossref

Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH, Ferry T (2010). HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early Mortality. American Journal of Respiratory and Critical Care Medicine 181(20):80-86.
Crossref

Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH (2010). HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. American Journal of Respiratory and Critical Care Medicine 181(1): 80-86.
Crossref

Hainlifescience (2015). Genotype MTBDR, pp. 1-10.

Hirpa S, Medihn G, Girma BE (2013). Determinants of multi drug- resistant tuberculosis in patients who underwent first-line treatment Addis Ababa: A case-control study. BMC Public Health 13:2-9.
Crossref

Ioannidis P, Papaventsis D, Karabela S, Nikolaou S, Panagi M, Raftopoulou E, Konstantinidou E, Marinou I, Kanavaki S (2011). Cepheid GeneXpert MTB/RIF Assay for Mycobacterium tuberculosis Detection and Rifampin Resistance Identification in Patients with Substantial Clinical Indications of Tuberculosis and Smear-Negative Microscopy Results. Journal of Clinical Microbiology 49(8):3068-3070.
Crossref

Ismail N, Ismail F, Omar SV, Blows L, Gardee Y, Koornhof H, Onyebujoh PC (2018). Drug resistant tuberculosis in Africa: Current status, gaps and opportunities. African Journal of Laboratory Medicine 7(2):1-11.
Crossref

Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, Serbulenco A, Zignol M, Dadu A, Dara M (2013). Assessing spatial heterogeneity of MDR-TB in a high burden country. European Respiratory Journal 42(5):1-25.
Crossref

Kent PI, Kubica GP (1985). Public health Mycobacteriology: A guide for the level III laboratory. Atlanta: Center for disease control (1st Edition). CDC.

Kibret KT, Moges Y, Memiah P, Biadgilign S (2017). Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: A systematic review and meta-analysis of published studies. Infectious Diseases of Poverty, pp. 1-8.
Crossref

Kidenya BR, Webster LE, Behan S, Kabangila R, Peck RN, Mshana SE, Fitzgerald DW (2014). Epidemiology and genetic diversity of multidrug-resistant tuberculosis in East Africa. Tuberculosis 94(1):1-7.
Crossref

Kidenya B, Webster L, Behan L, Kabangila R, Mshana S, Oksana O (2014). Epidemiology and genetic diversity of multidrug-resistant tuberculosis in East Africa. Tuberculosis (Edinb) 94(1):675-680.
Crossref

Leung CC, Yew WW, Chan CK, Tam, CM, Lam CW, Chang KC, Chau CH, Lau KS, Law WS (2003). Smoking and tuberculosis in Hong Kong. International Journal of Tuberculosis and Lung Disease 7:980-986.

Liang Y, Harris FL, LAS B (2015). Alcohol Induced Mitochondrial Oxidative Stress and Alveolar Macrophage Dysfunction. BioMed Research International, pp. 1-14.
Crossref

Meaza A, Kebede A, Yaregal Z, Dagne Z, Moga S, Yenew B, et al. (2017). Evaluation of genotype MTBDR plus Ver 2 . 0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infectious Diseases, P. 8.
Crossref

Mesfin YM, Hailemariam D, Biadgilign S, Biadglign S, Kibret KT (2014). Association between HIV/AIDS and multi-drug resistance tuberculosis: A systematic review and meta-analysis. PloS ONE 9(1):e82235.
Crossref

Ministry of Health, Community development, Gender (2018). TB Prevalence in Tanzania. The National Tuberculosis and Leprosy Programme

Monadil HA, Alian AA, Mohamed AH, Dan K, Godman B (2019). Predictors of Multidrug-Resistant Tuberculosis. Antibiotics 8(90):1-11.
Crossref

Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B (2015). Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. African Journal of Health Sciences 15(2):368-377.
Crossref

Nino M, Ekaterina Z, Natalia V, Ekaterina K, Henry MB, George K, Carlos del R, Archil S, Kourbatova, Thea Jibuti, Natalia Shubladze TK (2009). High Prevalence of Multidrug-Resistant Tuberculosis in Georgia. International Journal of Infectious Diseases 12(6):635-644.
Crossref

Ormerod LP (2005). Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. British Medical Bulletin 73(1):17-24.
Crossref

Participants' Manual: National comprehensive tuberculosis, leprosy and TB/HIV training for general health workers (2011). Federal Ministry of Health of Ethiopia, pp. 1-233.

Mai TQ, Martinez E, Menon R, Van Anh NT, Hien NT, Marais BJ, Sintchenko V (2006). Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. International Journal of Tuberculosis and Lung Disease 10:160-166.

Ryu YJ (2015). Diagnosis of Pulmonary Tuberculosis: Recent Advances and Diagnostic Algorithms. Tuberculosis and Respiratory Diseases 78(2):64.
Crossref

Schreiber YS, Herrera AF, Wilson D, Wallengren K, Draper R, Muller J, Dawood H, Doucette S, Cameron DW, Alvarez GG (2009). Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area. The International Journal of Tuberculosis and Lung Disease 13(10):1274-1280.

Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH (2019). A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New England Journal of Medicine 320(9):545-550.
Crossref

Seyoum B, Demissie M, Worku A, Bekele S, Aseffa A (2014). Prevalence and Drug Resistance Patterns of Mycobacterium tuberculosis among New Smear Positive Pulmonary Tuberculosis Patients in Eastern Ethiopia. Tuberculosis Research and Treatment pp. 1-7.
Crossref

Sharma SK, Mohan A (2006). Multidrug-resistant tuberculosis: A menace that threatens to destabilize tuberculosis control. Chest 130:261-272.
Crossref

Shimeles E, Enquselassie F, Tilahun M, Mekonnen A (2019). Risk Factors for Multidrug-Resistant Tuberculosis and Characteristics of Cases : A Case-Control Study of Patients Attending ALERT General Hospital in Addis Ababa, Ethiopia. Journal of Respiratory Disease 9:1-17.
Crossref

Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M (2006). Fluorescence versus conventional sputum smear microscopy for tuberculosis: A systematic review. Lancet 6:570-581.
Crossref

Stop TB Partneship. (2018). Global Plan to End TB: 2018-2022, pp. 1-32.

Tamary HL, Isack L, Edson M, Kajiru GK (2019). Predictors of Treatment Outcomes among Multidrug Resistant Tuberculosis Patients in Tanzania. Hindawi Tuberculosis Research and Treatment, pp. 1-10.
Crossref

Vashakidze L, Salakaia A, Shubladze N, Cynamon M, Barbakadze K, Kikvidze M, Papitashvili L, Nonikashvili M, Solomonia N, Bejanishvili N, Khurtsilava I (2009). Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia. The International Journal of Tuberculosis and Lung Disease 13(9):1148-1153.

Wahab F, Ashraf S, Khan N, Anwar RAM (2009). Risk factors for multidrug resistant tuberculosis in patients at Tertiary Care Hospital, Peshawar. Journal of the College of Physicians and Surgeons Pakistan 19:162-164.

Weinstock DM, Hahn O, Wittkamp M, Sepkowitz KA, Khechinashvili GBH (2001). Risk for tuberculosis infection among internally displaced persons in the Republic of Georgia. International Journal of Tuberculosis and Lung Disease 5(2):164-269.

Wells DC, Peter CJ, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K (2007). HIV infection and multidrug- resistant tuberculosis-the perfect storm. Journal of Infectious Diseases 196:S86-S88.
Crossref

World Health Organization (2016). World Health Organization. Multidrug-resistant tuberculosis (MDR-TB) 2016 Update. Geneva.

World Health Organization (2003). Adherence to Long - Termtherapies pp. 1-16.
Crossref

World Health Organization (2012a). Global Tuberculosis Report.

World Health Organization (2012b). Report on MDR-TB (Issue 1).

World Health Organization (2014a). Global status report on alcohol and health.

World Health Organization (2014b). Global tuberculosis report pp. 1-118.

World Health Organization (2014c). World Health Organization. Antimicrobial resistance: global report on surveillance.

World Health Organization (2015). End TB strategy pp. 1-20.

World Health Organization (2017). Global Tuberculosis.

World Health Organization (2018). Global tuberculosis report.

World Health Organization (2011). Guidelines for the programmatic management of Multidrug-resistant Tuberculosis.

World Health Organization (2014). Companion handbook.

World Health Organization (2012c) . Burundi tuberculosis profile 2012. Geneva, Switzerland: WHO; 2012. 

View

World Health Organization (2012d). Kenya tuberculosis profile 2012. Geneva, Switzerland: WHO; 2012. 

View

World Health Organization (2012e). Rwanda tuberculosis profile 2012. Geneva, Switzerland: WHO; 2012. 

View

World Health Organization (2012f). Tanzania tuberculosis profile 2012. Geneva, Switzerland: WHO; 2012. 

View

World Health Organization (2012g). Uganda tuberculosis profile 2012. Geneva, Switzerland: WHO; 2012. 

View

Zalesky R, Abdullajev F, Khechinashvili G, Safarian M, Madaras T, Grzemska, Englund E, Dittmann S, Raviglione M (1999). Tuberculosis control in the Caucasus: Successes and constraints in DOTS implementation. International Journal of Tuberculosis and Lung Disease 3(5):394-401.